Myeloproliferative Neoplasms

By Harry P. Erba, MD, PhD, Duke Cancer Institute, Krisstina Gowin, DO, University of Arizona Cancer Center, Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Polycythemia Vera: Ruxolitinib Trial Data

By Harry P. Erba, MD, PhD, Duke Cancer Institute, Krisstina Gowin, DO, University of Arizona Cancer Center, Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Polycythemia Vera: Switching Therapy

By Harry P. Erba, MD, PhD, Duke Cancer Institute, Krisstina Gowin, DO, University of Arizona Cancer Center, Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Treatment Options for High-Risk Polycythemia Vera

By Harry P. Erba, MD, PhD, Duke Cancer Institute, Krisstina Gowin, DO, University of Arizona Cancer Center, Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Management of Low-Risk Polycythemia Vera

Latest Videos

Management of Accelerated Phase Myeloproliferative Neoplasms

Novel Agents Under Investigation for Myelofibrosis

Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022

Efficacy and Safety of JAK Inhibitors for Myelofibrosis

New JAK Inhibitors in Myelofibrosis Treatment

Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials

Risk Stratification for Myelofibrosis

Myeloproliferative Neoplasms: Myelofibrosis

Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

CME Content

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Register now!

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

In-Person + Virtual Event

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

March 24, 2026

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

In-Person + Virtual Event

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

February 19, 2026

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Polycythemia Vera: Monitoring Patients

July 7th 2020

Polycythemia Vera: Risk Assessment

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Prognostic Markers

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Bone Marrow Biopsies

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Diagnostic Work-up

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Characterization of Myeloproliferative Neoplasms

ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

BySrdan Verstovsek, MD, PhD

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

European Commission Approves Luspatercept for Transfusion-Dependent Anemia in MDS or Beta-Thalassemia

ByKristi Rosa

June 26th 2020

The European Commission has approved luspatercept-aamt (Reblozyl) as a treatment for patients with transfusion-dependent anemia from very low-, low-, and intermediate-risk myelodysplastic syndromes with ring sideroblasts who had unsatisfactory response or are not candidates for erythropoietin-based therapy, and patients with transfusion-dependent anemia linked with beta thalassemia.

CPI-0610 Shows Practice-Changing Potential in Myelofibrosis

ByJessica Hergert

June 25th 2020

The novel BET inhibitor CPI-0610 demonstrated clinical activity with or without ruxolitinib in patients with JAK inhibitor-naïve and JAK inhibitor-exposed or -intolerant myelofibrosis.

Dr. Cortes on the Benefit of Ruxolitinib in MPNs

ByJorge Cortes, MD

June 17th 2020

Jorge E. Cortes, MD, discusses the benefits of ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms.

Dr. Fleur-Lominy on Targeted Pathways in MPNs

ByShella Saint Fleur-Lominy, MD, PhD

June 15th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Real-World Evidence Supports Ruxolitinib Reinitiation in Myelofibrosis

ByJessica Hergert

June 10th 2020

Naveen Pemmaraju, MD, discusses the potential benefit of rechallenging ruxolitinib in patients with myelofibrosis.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Utility of Ruxolitinib in Myelofibrosis

ByJohn O. Mascarenhas, MD

June 6th 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.

Dr. Hoffman on the Current Polycythemia Vera Treatment Paradigm

ByRonald Hoffman, MD

June 5th 2020

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

FDA Accepts Application for Ropeginterferon Alfa-2b for Polycythemia Vera

ByJason M. Broderick

June 5th 2020

The FDA has accepted an application for ropeginterferon alfa-2b for use as a treatment for patients with polycythemia vera.

Dr. Cortes on Future Directions in MPNs

ByJorge E. Cortes, MD

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Hepcidin Mimetic PTG-300 Shows Early Promise in Polycythemia Vera

ByJessica Hergert

May 19th 2020

The first-in-class, synthetic hepcidin mimetic agent PTG-300 is being investigated in an ongoing phase 2 clinical trial, with the goal of introducing a novel therapeutic agent to the limited armamentarium in polycythemia vera.

Ruxolitinib Discontinuation in Myelofibrosis Leads to Increased Morbidity Burden, Underscoring Unmet Need

ByKristi Rosa

May 18th 2020

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Alvocidib Trial Launches in MDS

ByJason Broderick

May 14th 2020

The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.

Dr. Bose on Novel Agents Under Investigation in Myelofibrosis